Deykin A - Search Results

1

Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction.

Tofovic SP, Salah EM, Smits GJ, Whalley ET, Ticho B, Deykin A, Jackson EK. Tofovic SP, et al. Among authors: deykin a. J Pharmacol Exp Ther. 2016 Feb;356(2):333-40. doi: 10.1124/jpet.115.228841. Epub 2015 Nov 19. J Pharmacol Exp Ther. 2016. PMID: 26585572 Free PMC article.

2

Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure.

Gottlieb SS, Ticho B, Deykin A, Abraham WT, Denofrio D, Russell SD, Chapman D, Smith W, Goldman S, Thomas I. Gottlieb SS, et al. Among authors: deykin a. J Clin Pharmacol. 2011 Jun;51(6):899-907. doi: 10.1177/0091270010375957. Epub 2010 Oct 6. J Clin Pharmacol. 2011. PMID: 20926754 Clinical Trial.

3

Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment.

Li Z, Gan LS, Marbury T, Lasseter KC, Natarajan A, Stecher S, Wei D, Yang L, Freedman D, Deykin A. Li Z, et al. Among authors: deykin a. J Clin Pharmacol. 2012 Apr;52(4):543-51. doi: 10.1177/0091270011400413. Epub 2011 May 24. J Clin Pharmacol. 2012. PMID: 21610206 Clinical Trial.

4

Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.

Hu X, Hang Y, Cui Y, Zhang J, Liu S, Seddighzadeh A, Deykin A, Nestorov I. Hu X, et al. Among authors: deykin a. J Clin Pharmacol. 2017 Aug;57(8):1005-1016. doi: 10.1002/jcph.883. Epub 2017 Apr 10. J Clin Pharmacol. 2017. PMID: 28394418 Free PMC article. Clinical Trial.

5

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.

Hu X, Cui Y, White J, Zhu Y, Deykin A, Nestorov I, Hung S. Hu X, et al. Among authors: deykin a. Br J Clin Pharmacol. 2015 Mar;79(3):514-22. doi: 10.1111/bcp.12521. Br J Clin Pharmacol. 2015. PMID: 25265472 Free PMC article. Clinical Trial.

6

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Calabresi PA, et al. Among authors: deykin a. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30. Lancet Neurol. 2014. PMID: 24794721 Clinical Trial.

7

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Arnold DL, et al. Among authors: deykin a. BMC Neurol. 2014 Dec 31;14:240. doi: 10.1186/s12883-014-0240-x. BMC Neurol. 2014. PMID: 25551571 Free PMC article. Clinical Trial.

8

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.

Calabresi PA, Arnold DL, Sangurdekar D, Singh CM, Altincatal A, de Moor C, Engle B, Goyal J, Deykin A, Szak S, Kieseier BC, Rudick RA, Plavina T. Calabresi PA, et al. Among authors: deykin a. Mult Scler. 2021 Sep;27(10):1497-1505. doi: 10.1177/1352458520972573. Epub 2020 Dec 14. Mult Scler. 2021. PMID: 33307998 Free PMC article. Clinical Trial.

9

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Among authors: deykin a. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147 Clinical Trial.

10

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Among authors: deykin a. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters